Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones

Journal of Neuroimmunology

Volumn 98, Issue 2, 1999, Pages 147-156

  Pette, Martin ^a,b   Muraro, Paolo A ^a,c   Pette, Dagmar F ^a   Dinter, H ^d   McFarland, Henry F ^a   Martin, Roland ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF CHIETI   (Italy)

^d BAYER AG   (Germany)

Author keywords

Multiple sclerosis; Phosphodiesterase inhibition; Rolipram; T lymphocytes

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOTOXIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANTIBODIES; AUTOANTIGENS; BUCLADESINE; CELL DIVISION; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOTOXIN-ALPHA; MULTIPLE SCLEROSIS; MYELIN PROTEINS; MYELIN SHEATH; OLIGONUCLEOTIDE PROBES; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; ROLIPRAM; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032981341     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00088-0     Document Type: Article

References (38)

1. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., Boumpas D.T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J. Immunol. 148:1992;2845-2852.
2. Baeuerle P.A., Henkel T. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
3. Betz M., Fox B.S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146:1991;108-113.
4. Canella B., Gao Y.L., Brosnan C.F., Raine C.S. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J. Neurosci. Res. 45:1996;735-746.
5. Cantrell D. T cell antigen receptor signal transduction pathways. Annu. Rev. Immunol. 14:1996;259-274.
6. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:1993;353-360.
7. Dent, G., Giembycz, M.A., 1996a. Interaction of PDE4 inhibitors with enzymes and cell functions. In: Schudt, C., Dent, G., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors. Academic Press, San Diego, pp. 111-126.
8. Dent, G., Rabe, K.F., 1996b. Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes and cellular function. In: Schudt, C., Dent, G., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors. Academic Press, San Diego, pp. 41-64.
9. Dinter H.J., Onuffer J., Faulds D., Perez H.D. Phosphodiesterase type 4 inhibitors in the treatment of multiple sclerosis. J. Mol. Med. 75:1997;85-102.
10. Ekholm D., Hemmer B., Gao G., Vergelli M., Martin R., Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase PDE3 and PDE4 activities in human T cell clones specific for myelin basic protein. J. Immunol. 159:1997;1520-1529.
11. Engels P., Fichtel K., Lübbert H. Expression and regulation of human and rat phosphodiesterase type 4 isogenes. FEBS Lett. 350:1994;291-295.
12. Essayan D.M., Kagey-Sobotka A., Lichtenstein L.M., Huang S.K. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 282:1997;505-512.
13. Farrar W.L., Evans S.W., Rapp U.R., Cleveland J.L. Effects of anti-proliferative cyclic AMP on interleukin 2-stimulated gene expression. J. Immunol. 139:1987;2075-2080.
14. Frei K., Eugster H.P., Fontana A. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1997;2177.
15. Genain C.P., Roberts T., Davis R.L., Nguyen M.H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:1995;3601-3605.
16. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., Barnes P.J. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118:1996;1945-1958.
17. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:1995;333-342.
18. Jung S., Zielasek J., Kollner G., Donhauser T., Toyka K., Hartung H.P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68:1996;1-11.
19. Laxminarayana D., Kammer G.M. Activation of type I protein kinase A during receptor-mediated human T lymphocyte activation. J. Immunol. 156:1996;497-506.
20. Lederer J.A., Liou J.S., Kim S., Rice N., Lichtman A.H. Regulation of NF-kappaB activation in T helper 1 and T helper 2 cells. J. Immunol. 156:1996;56-63.
21. Martin R., Utz U., Coligan J.E., Richert J.R., Flerlage M., Robinson E., Stone R., Biddison W.E., McFarlin D.E., McFarland H.F. Diversity in fine specificity and T cell receptor usage of the human CD4+cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 148:1992;1359-1366.
22. Mary D., Aussel C., Ferrua B., Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139:1987;1179-1184.
23. Munoz E., Zubiaga A.M., Merrow M., Sauter N.P., Huber B.T. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J. Exp. Med. 172:1990;95-103.
24. Muraro P.A., Vergelli M., Kalbus M., Banks D.E., Nagle J.W., Tranquill L., Nepom G.T., Biddison W.E., McFarland H.F., Martin R. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 100:1997;339-349.
25. Neumann M., Grieshammer T., Chuvpilo S., Kneitz B., Lohoff M., Schimpl A., Franza B.R. Jr., Serfling E. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J. 14:1995;1991-2004.
26. Nyman U., Mussener A., Larsson E., Lorentzen J., Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type 4 phosphodiesterase inhibitor Rolipram. Clin. Exp. Immunol. 1997:1997;415-419.
27. Paliogianni F., Boumpas D.T. Prostaglandin E2 inhibits the nuclear transcription of the human interleukin 2, but not the Il-4, gene in human T cells by targeting transcription factors AP-1 and NF-AT. Cell Immunol. 171:1996;95-101.
28. Paliogianni F., Kincaid R.L., Boumpas D.T. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J. Exp. Med. 178:1993;1813-1817.
29. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Borner T., Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64:1996;193-200.
30. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1993;1745-1751.
31. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1994;1434-1440.
32. Sommer N., Löschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmüller A., Fontana A. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:1995;244-248. see comments.
33. Sommer N., Martin R., McFarland H.F., Quigley B., Canella B., Raine C.S., Scott D.E., Löschmann P.A., Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79:1997;54-61.
34. Spits H., Yssel H., Takebe Y., Arai N., Yokota T., Lee F., Arai K., Banchereau J., de-Vries J.E. Recombinant interleukin 4 promotes the growth of human T cells. J. Immunol. 139:1987;1142-1147.
35. Tamir A., Granot Y., Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J. Immunol. 157:1996;1514-1522.
36. Tenor H., Staniciu L., Schudt C., Hatzelmann A., Wendel A., Djukanovic R., Church M.K., Shute J.K. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+T lymphocytes. Clin. Exp. Allergy. 25:1995;616-624.
37. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:1995;775-779.
38. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531-1534.